Arrhythmias/Electrophysiology
Subepicardial Cardiomyopathy: a disease underlying J-wave syndromes and idiopathic ventricular fibrillation
29 May, 2023 | 10:38h | UTC
Commentary on Twitter
#StateOfTheArt: Subepicardial cardiomyopathy – a disease underlying J-wave syndromes and idiopathic ventricular fibrillation @BehrElijah @Chiara_Scrocco @bjboukens @DrCJMiles #AHAJournals https://t.co/brITevJfIh pic.twitter.com/HWw8gcmE33
— Circulation (@CircAHA) May 26, 2023
Consensus Statement | Management of arrhythmias during pregnancy
23 May, 2023 | 13:00h | UTC2023 HRS Expert Consensus Statement on the Management of Arrhythmias During Pregnancy – Heart Rhythm
News Release: Management of Arrhythmias During Pregnancy Consensus Statement Emphasizes Shared Decision-Making – European Heart Rhythm
Consensus Statement | Practical management of the remote device clinic
23 May, 2023 | 12:58h | UTC
Guideline | Cardiac physiologic pacing for the avoidance and mitigation of heart failure
23 May, 2023 | 12:55h | UTCNews Release: New clinical practice guideline on cardiac physiological pacing – Elsevier
Atrial fibrillation incidence associated with exposure to anticancer drugs used as monotherapy in clinical trials
10 May, 2023 | 15:54h | UTCEditorials:
Atrial Fibrillation With Modern Cancer Treatment: More Common Than We Think – JACC: CardioOncology
Commentary on Twitter
Annual incidence rate of #AFib assoc w/ anticancer drugs were ⬆️ in pts w/ hematologic malig. It was found for #ibrutinib 4.92 (95% CI: 2.91-8.31), #clofarabine 2.38 (95% CI: 0.66-8.55), & #ponatinib 2.35 (95% CI: 1.78-3.12) per 100 person-yrs https://t.co/W2RGMrE37F… pic.twitter.com/NnbmUVcci5
— JACC Journals (@JACCJournals) April 27, 2023
Review | Causes of sudden death
9 May, 2023 | 14:16h | UTCCauses of sudden death – European Heart Journal Supplements
See all articles in the series here
Review | The bidirectional association between atrial fibrillation and myocardial infarction
8 May, 2023 | 12:54h | UTCThe bidirectional association between atrial fibrillation and myocardial infarction – Nature Reviews Cardiology (if the link is paywalled, try this one)
Commentary on Twitter
In our latest Review, @JKornej, @EmeliaBenjamin et al. explore the bidirectional association between #AtrialFibrillation and myocardial infarction: https://t.co/K3iH24e57U pic.twitter.com/sKBrhRJXf3
— Nature Reviews Cardiology (@NatRevCardiol) April 17, 2023
M-A | Direct oral anticoagulants versus warfarin across the spectrum of kidney function in patients with AF
3 May, 2023 | 15:32h | UTCDirect Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF – Circulation (free for a limited period)
Commentary on Twitter
Direct Oral Anticoagulants versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses from COMBINE AF @jlharrington_md #AHAJournals https://t.co/6Rzlt09m9W pic.twitter.com/2oknvnken8
— Circulation (@CircAHA) April 18, 2023
Oral anticoagulation in patients with advanced CKD and atrial fibrillation: beyond anticoagulation
2 May, 2023 | 13:20h | UTC
RCT | Comparison of three different substrate ablation strategies for persistent atrial fibrillation
26 Apr, 2023 | 14:18h | UTC
RCT | No difference in atrial fibrillation recurrence with early vs. delayed AF ablation at 12 months
24 Apr, 2023 | 13:49h | UTCImpact of Early Versus Delayed Atrial Fibrillation Catheter Ablation on Atrial Arrhythmia Recurrences – European Heart Journal (link to abstract – $ for full-text. Free PDF may be available here)
Commentary on Twitter
Early versus delayed ablation strategy in atrial fibrillation: read the impact on arrhythmia free survival on #EHJ!#EHRA2023 #EHJ #cardiotwitter #ablation #AF @ESC_Journals @escardio https://t.co/RW9RPry5Vi pic.twitter.com/2iHW49T3Wp
— EHJ Editor-in-Chief (@ehj_ed) April 18, 2023
Global Survey | Incidence, management and prognosis of esophageal fistula after atrial fibrillation catheter ablation
19 Apr, 2023 | 13:14h | UTCCommentary: Esophageal Fistula Still a Rare but Deadly Complication of AF Ablation: POTTER-AF – TCTMD
Commentary from the author on Twitter
🌎The POTTER-AF study
➡️published #EHJ online
➡️138 oesophageal fistulas
➡️incidence 0,025% overall, 🔥RF 0.038%, ❄️CRYO 0.0015%
☠️Mortality: 90% if treated conservative!
🙏V. Schmidt, @KeelaniAhmad @ChristianHeeger@AGEP_DGK @ESC_Journals #UKSHhttps://t.co/jTmC36wlYQ #EPeeps pic.twitter.com/3lntY6lR6H— Roland Tilz (@RolandTilz) April 16, 2023
EHRA expert consensus document on the management of arrhythmias in frailty syndrome
18 Apr, 2023 | 12:58h | UTC
Cohort Study | Value of screening for the risk of sudden cardiac death in young competitive athletes
12 Apr, 2023 | 13:11h | UTC
RCT | Augmented ablation fails to outperform standard ablation in paroxysmal AF patients
11 Apr, 2023 | 13:57h | UTCStandard vs Augmented Ablation of Paroxysmal Atrial Fibrillation for Reduction of Atrial Fibrillation Recurrence: The AWARE Randomized Clinical Trial – JAMA Cardiology (link to abstract – $ for full-text)
Commentary: Augmented Ablation Adds No Benefit in Prevention of Recurrent Atrial Arrhythmia – HCP Live
Commentary on Twitter
The AWARE Trial tested an augmented WACA in pts with paroxysmal AF. A high single procedure freedom from AF was noted without an improvement compared to single WACA. There might be a “ceiling effect” to catheter ablation in patients with paroxysmal AF. https://t.co/2ihyHwHlTA pic.twitter.com/waSbp0QF1a
— JAMA Cardiology (@JAMACardio) March 22, 2023
Study identifies top 3 anticancer drugs with highest atrial fibrillation rates
11 Apr, 2023 | 13:55h | UTCCommentary: More AF Surveillance Needed in Chemotherapy Trials, Meta-analysis Hints – TCTMD
Adolescent sudden cardiac death: the role of underlying conditions and physical activity
5 Apr, 2023 | 13:26h | UTCSudden Cardiac Death Among Adolescents in the United Kingdom – Journal of the American College of Cardiology (link to abstract – $ for full-text)
Commentary on Twitter
Among the causes of SCD in adolescents, arrhythmogenic #cardiomyopathy, coronary artery anomalies & commotio cordis are more common in young athletes who die suddenly than in similarly aged sedentary individuals.
Read more on this https://t.co/VHRIiNz1hE… pic.twitter.com/N3bev3Nv8i
— JACC Journals (@JACCJournals) March 14, 2023
SCAI/HRS Expert consensus statement on transcatheter left atrial appendage closure
31 Mar, 2023 | 13:44h | UTCSCAI/HRS Expert Consensus Statement on Transcatheter Left Atrial Appendage Closure – JSCAI
Key Points: Consensus Statement on Transcatheter LA Appendage Closure – American College of Cardiology
Commentaries:
SCAI/HRS Consensus Document Covers the Ins and Outs of LAAO – TCTMD
Coffee consumption vs. caffeine avoidance: cardiac ectopy, daily steps, and sleep impacts
27 Mar, 2023 | 13:32h | UTCSummary: A prospective, randomized, case-crossover trial studied the acute health effects of caffeinated coffee consumption in 100 ambulatory adults.
Participants were monitored using continuous electrocardiogram devices, wrist-mounted accelerometers, and ongoing glucose monitoring systems for 14 days. They received daily text messages instructing them to either consume caffeinated coffee or abstain from caffeine.
The primary outcome was the mean number of daily premature atrial contractions. Results indicated that caffeinated coffee consumption didn’t lead to significantly more daily premature atrial contractions compared to caffeine avoidance. However, it was associated with a higher number of daily premature ventricular contractions, increased daily steps, and reduced nightly sleep.
Article: Acute Effects of Coffee Consumption on Health among Ambulatory Adults – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
What to know about new research on coffee and heart risks – Associated Press
CRAVE Trials Offers Most Comprehensive Overview Yet of Impact of Coffee, Caffeine Intake – HCP Live
Acute Effects of Coffee Consumption on Health – American College of Cardiology
BRAVO Registry | Brugada substrate ablation results in a significant reduction of ventricular fibrillation events
27 Mar, 2023 | 13:11h | UTCLong-Term Outcomes of Brugada Substrate Ablation: A Report from BRAVO (Brugada Ablation of VF Substrate Ongoing Multicenter Registry) – Circulation (free for a limited period)
Study shows increased bleeding complications in ESKD patients undergoing AF ablation
24 Mar, 2023 | 13:09h | UTCSummary: The study analyzed 347 procedures in 307 patients with end-stage kidney disease (ESKD) undergoing atrial fibrillation (AF) catheter ablation in 12 referral centers in Japan.
Despite a vast majority of patients having subtherapeutic international normalized ratio (INR) values during the peri-procedural period, 35 patients (10%) experienced major complications, with the majority being major bleeding events (19 patients; 5.4%), including 11 cases of cardiac tamponade (3.2%). There were also two peri-procedural deaths (0.6%), both related to bleeding events. A pre-procedural INR value of 2.0 or higher was identified as the only independent predictor of major bleeding.
Current peri-procedural anticoagulation guidelines state that patients undergoing AF ablation should be under therapeutic anticoagulation throughout the peri-procedural period. The findings of this study suggest that these guidelines may not be appropriate for ESKD patients undergoing the procedure, and the role of peri-procedural anticoagulation in this population should be further investigated.
Commentary on Twitter
Peri-procedural anticoagulation in patients with end-stage kidney disease undergoing #afib ablation 👉 despite undertreatment with warfarin, the rate of haemorrhagic complications is high! https://t.co/3W8gEtZYdy#kidney #afib #anticoagulation #ablation #cardiotwitter #europace pic.twitter.com/vI27UeIpRf
— European Society of Cardiology Journals (@ESC_Journals) March 16, 2023
M-A | Posterior pericardiotomy reduces the risk of atrial fibrillation after cardiac surgery
22 Mar, 2023 | 13:18h | UTCPosterior pericardiotomy for the prevention of atrial fibrillation after cardiac surgery: a systematic review and meta-analysis of 25 randomised controlled trials – EuroIntervention (link to abstract – $ for full-text)
Related:
SR | Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation
20 Mar, 2023 | 13:41h | UTCSummary: This systematic review and meta-analysis assessed the efficacy of Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation (AF). The review included nine randomized controlled trials involving 3,269 participants.
The analysis found that Class I and/or III antiarrhythmic drugs may reduce the recurrence of atrial tachyarrhythmias at 0 to 3 months and likely reduce recurrence at > 3 to 6 months. However, beyond six months, the evidence is uncertain, and the benefit of antiarrhythmic drugs may not persist. Additionally, the use of these drugs post-ablation likely reduces hospitalizations for atrial tachyarrhythmias by approximately 57% at 0 to 3 months.
The use of Class I and/or III antiarrhythmic drugs did not increase the risk of thromboembolic events, myocardial infarction, all-cause mortality, or the need for repeat ablation.
AHA Scientific Statement | Atrial fibrillation occurring during acute hospitalization
14 Mar, 2023 | 14:04h | UTC
Review | Orthostatic tachycardia after covid-19
14 Mar, 2023 | 13:48h | UTCOrthostatic tachycardia after covid-19 – The BMJ
Commentary: Key steps for diagnosis and management of orthostatic tachycardia after COVID-19 – News Medical